Jazz Pharmaceuticals JAZZ Intangible Amortization
Intangible Amortization at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's intangible amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's intangible amortization?
- Jazz Pharmaceuticals (JAZZ) reported intangible amortization of $172.3M in Q1 2026.
- How has Jazz Pharmaceuticals's intangible amortization changed year-over-year?
- Jazz Pharmaceuticals's intangible amortization increased by 11.6% year-over-year, from $154.4M to $172.3M.
- What does intangible amortization mean?
- The non-cash accounting expense of spreading the cost of acquired intangible assets over time.
- How do you interpret intangible amortization?
- High amortization reflects significant past acquisition activity and the gradual consumption of acquired intellectual property value.
- How does intangible amortization compare across companies?
- High for companies with significant M&A history; standard across the pharmaceutical sector.